Here's how tesamorelin vs sermorelin and other GHRH peptides compare: GHRH Peptide Comparison Table Property Tesamorelin Sermorelin CJC-1295 (No DAC) CJC-1295 DAC FDA Status FDA Approved (Egrifta) Previously approved, now discontinued Not approved Not approved Amino Acids 44 (modified GHRH) 29 (GHRH 1-29) 29 + modifications 29 + Drug Affinity Complex Half-Life ~26-38 minutes ~10-20 minutes ~30 minutes ~6-8 days Mechanism GHRH receptor agonist GHRH receptor agonist GHRH receptor agonist GHRH receptor agonist (extended) Clinical Trial Data Extensive (Phase 3 completed) Limited (older studies) Limited (Phase 1/2) Limited Primary Research Use Lipodystrophy, NAFLD, body composition GH deficiency research GH axis research Extended GH release research Key Differentiators Tesamorelin's advantages: Only GHRH analog with current FDA approval Extensive Phase 3 clinical trial data Documented efficacy for visceral fat reduction Well-characterized safety profile from prescription use Sermorelin note: Previously FDA-approved (1997) for pediatric growth hormone deficiency but discontinued by manufacturers no longer available as a prescription product in the US
more Product information "Heptanoyl-L-carnitine (chloride)" Heptanoyl-L-carnitine is a medium-chain acylcarnitine and derivative of L-carnitine (Cay-21489).Formal Name: (R)-3-carboxy-N,N,N-trimethyl-2-[(1-oxoheptyl)oxy]-1-propanaminium, monochloride
However, you can use your HSA or FSA card for payment
2 Of these adverse effects, gastrointestinal effects are most commonly reported
No Blood Sugar or Insulin Impact (Human Data) Evidence quality: Strong (clinical confirmation) In contrast to full-length growth hormone which reliably worsens insulin sensitivity chronic AOD-9604 treatment showed no adverse effect on carbohydrate metabolism
8.7.19 Cindy nguyen said: Hi love, Thanks for sharing all of this
